EHC

SEC source: 0001127602-20-015817 · form4.xml · nonDerivative · entry 1

Williams Terrance · CIK 0001798480 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,059

F1 · shares: Annual award of restricted stock pursuant to the Corporation's 2016 Omnibus Performance Incentive Plan.

SEC source: 0001127602-20-015815 · form4.xml · nonDerivative · entry 1

SHAW L EDWARD JR · CIK 0001183337 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 94,844

F1 · shares: Annual award of restricted stock pursuant to the Corporation's 2016 Omnibus Performance Incentive Plan.

SEC source: 0001127602-20-015814 · form4.xml · nonDerivative · entry 1

SCHLICHTING NANCY M · CIK 0001376358 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,076

F1 · shares: Annual award of restricted stock pursuant to the Corporation's 2016 Omnibus Performance Incentive Plan.

SEC source: 0001127602-20-015813 · form4.xml · nonDerivative · entry 1

MAUPIN JOHN E JR D D S · CIK 0001189149 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 77,131

F1 · shares: Annual award of restricted stock pursuant to the Corporation's 2016 Omnibus Performance Incentive Plan.

SEC source: 0001127602-20-015812 · form4.xml · nonDerivative · entry 1

Maryland Patricia Anne · CIK 0001798468 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,059

F1 · shares: Annual award of restricted stock pursuant to the Corporation's 2016 Omnibus Performance Incentive Plan.

SEC source: 0001127602-20-015809 · form4.xml · nonDerivative · entry 1

KATZ LESLYE G · CIK 0001193884 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,962

F1 · shares: Annual award of restricted stock pursuant to the Corporation's 2016 Omnibus Performance Incentive Plan.

SEC source: 0001127602-20-015808 · form4.xml · nonDerivative · entry 1

HIGDON LEO I JR · CIK 0001064587 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 76,321

F1 · shares: Annual award of restricted stock pursuant to the Corporation's 2016 Omnibus Performance Incentive Plan.

SEC source: 0001127602-20-015805 · form4.xml · nonDerivative · entry 1

HERMAN JOAN E · CIK 0001248398 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,962

F1 · shares: Annual award of restricted stock pursuant to the Corporation's 2016 Omnibus Performance Incentive Plan.

SEC source: 0001127602-20-015804 · form4.xml · nonDerivative · entry 1

ELSON CHARLES M · CIK 0001122124 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 78,911

F1 · shares: Annual award of restricted stock pursuant to the Corporation's 2016 Omnibus Performance Incentive Plan.

SEC source: 0001127602-20-015803 · form4.xml · nonDerivative · entry 1

CURL YVONNE M · CIK 0001135567 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 74,388

F1 · shares: Annual award of restricted stock pursuant to the Corporation's 2016 Omnibus Performance Incentive Plan.

SEC source: 0001127602-20-015799 · form4.xml · nonDerivative · entry 1

CORRELL DONALD L · CIK 0001199794 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 73,151

F1 · shares: Annual award of restricted stock pursuant to the Corporation's 2016 Omnibus Performance Incentive Plan.

SEC source: 0001127602-20-015798 · form4.xml · nonDerivative · entry 1

CHIDSEY JOHN · CIK 0001128484 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 117,750

F1 · shares: Annual award of restricted stock pursuant to the Corporation's 2016 Omnibus Performance Incentive Plan.

SEC source: 0001127602-20-015796 · form4.xml · nonDerivative · entry 1

CARMICHAEL GREG D · CIK 0001247734 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,059

F1 · shares: Annual award of restricted stock pursuant to the Corporation's 2016 Omnibus Performance Incentive Plan.

SEC source: 0001127602-20-013952 · form4.xml · nonDerivative · entry 2

CHIDSEY JOHN · CIK 0001128484 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 115,446

F2 · shares: This number represents the purchase of (a) 413 shares of common stock of Encompass Health Corporation (the "Company") pursuant to an election by the reporting person to participate in the Directors Deferred Stock Investment Plan of the Company (the "Plan") and (b) 194 shares associated with cash dividends on shares of the Company's common stock held under the Plan. The Plan is a non-qualified deferral plan adopted and approved by the Board of Directors, effective November 1, 2007, allowing non-employee directors to make elections during 2019 to defer fixed percentages of their directors fees for 2020. The amount each participant defers under the Plan is deducted, on a quarterly basis, from the directors fees the participant would otherwise have received in cash. The deferred fees fund the purchase of the Company's common stock by the Plan administrator in the market for the account of each participating director, and under the terms of the Plan, such stock is entitled to cash dividends that are reinvested by the Plan administrator in the Company's common stock. On April 15, 2020, the Company paid a dividend on common stock of $0.28 per share.

F3 · price: This per share price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $69.43 to $69.45, inclusive. The reporting person undertakes to provide to Encompass Health Corporation, any of its security holders, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within this range.

SEC source: 0001127602-20-013963 · form4.xml · nonDerivative · entry 2

SHAW L EDWARD JR · CIK 0001183337 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 92,540

F2 · shares: Pursuant to Encompass Health Corporation's Directors Deferred Stock Investment Plan (the "Plan"), cash dividends on shares of Encompass Health common stock held under the Plan are reinvested by the Plan administrator. The Plan is a nonqualified deferral plan adopted and approved by the Board of Directors, effective November 1, 2007, allowing non-employee directors to make elections to defer fixed percentages of their directors fees for the following year. The deferred fees fund the purchase of Encompass Health common stock by the Plan administrator in the market for the account of each participating director and such stock is entitled to cash dividends under the Plan. On April 15, 2020, the Company paid a dividend on common stock of $0.28 per share. The transaction reported on this Form 4 is a purchase of shares of common stock of Encompass Health in the market with that dividend payment.

SEC source: 0001127602-20-013961 · form4.xml · nonDerivative · entry 2

MAUPIN JOHN E JR D D S · CIK 0001189149 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 74,827

F2 · shares: Pursuant to Encompass Health Corporation's Directors Deferred Stock Investment Plan (the "Plan"), cash dividends on shares of Encompass Health common stock held under the Plan are reinvested by the Plan administrator. The Plan is a nonqualified deferral plan adopted and approved by the Board of Directors, effective November 1, 2007, allowing non-employee directors to make elections to defer fixed percentages of their directors fees for the following year. The deferred fees fund the purchase of Encompass Health common stock by the Plan administrator in the market for the account of each participating director and such stock is entitled to cash dividends under the Plan. On April 15, 2020, the Company paid a dividend on common stock of $0.28 per share. The transaction reported on this Form 4 is a purchase of shares of common stock of Encompass Health in the market with that dividend payment.

SEC source: 0001127602-20-013952 · form4.xml · nonDerivative · entry 1

CHIDSEY JOHN · CIK 0001128484 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 114,839

F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On April 15, 2020, Encompass Health paid a dividend on its common stock of $0.28 per share and the closing price was $69.76. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.

SEC source: 0001127602-20-013954 · form4.xml · nonDerivative · entry 1

CURL YVONNE M · CIK 0001135567 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 72,084

F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On April 15, 2020, Encompass Health paid a dividend on its common stock of $0.28 per share and the closing price was $69.76. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.

SEC source: 0001127602-20-013964 · form4.xml · nonDerivative · entry 1

Williams Terrance · CIK 0001798480 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 755

F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On April 15, 2020, Encompass Health paid a dividend on its common stock of $0.28 per share and the closing price was $69.76. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.

SEC source: 0001127602-20-013963 · form4.xml · nonDerivative · entry 1

SHAW L EDWARD JR · CIK 0001183337 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 92,480

F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On April 15, 2020, Encompass Health paid a dividend on its common stock of $0.28 per share and the closing price was $69.76. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.

SEC source: 0001127602-20-013962 · form4.xml · nonDerivative · entry 1

SCHLICHTING NANCY M · CIK 0001376358 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,772

F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On April 15, 2020, Encompass Health paid a dividend on its common stock of $0.28 per share and the closing price was $69.76. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.

SEC source: 0001127602-20-013960 · form4.xml · nonDerivative · entry 1

Maryland Patricia Anne · CIK 0001798468 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 755

F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On April 15, 2020, Encompass Health paid a dividend on its common stock of $0.28 per share and the closing price was $69.76. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.

SEC source: 0001127602-20-013961 · form4.xml · nonDerivative · entry 1

MAUPIN JOHN E JR D D S · CIK 0001189149 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 74,819

F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On April 15, 2020, Encompass Health paid a dividend on its common stock of $0.28 per share and the closing price was $69.76. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.

SEC source: 0001127602-20-013959 · form4.xml · nonDerivative · entry 1

KATZ LESLYE G · CIK 0001193884 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,658

F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On April 15, 2020, Encompass Health paid a dividend on its common stock of $0.28 per share and the closing price was $69.76. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.

SEC source: 0001127602-20-013958 · form4.xml · nonDerivative · entry 1

HIGDON LEO I JR · CIK 0001064587 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 74,017

F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On April 15, 2020, Encompass Health paid a dividend on its common stock of $0.28 per share and the closing price was $69.76. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.

SEC source: 0001127602-20-013956 · form4.xml · nonDerivative · entry 1

HERMAN JOAN E · CIK 0001248398 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,658

F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On April 15, 2020, Encompass Health paid a dividend on its common stock of $0.28 per share and the closing price was $69.76. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.

SEC source: 0001127602-20-013955 · form4.xml · nonDerivative · entry 1

ELSON CHARLES M · CIK 0001122124 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 76,607

F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On April 15, 2020, Encompass Health paid a dividend on its common stock of $0.28 per share and the closing price was $69.76. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.

SEC source: 0001127602-20-013953 · form4.xml · nonDerivative · entry 1

CORRELL DONALD L · CIK 0001199794 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 70,847

F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On April 15, 2020, Encompass Health paid a dividend on its common stock of $0.28 per share and the closing price was $69.76. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.

SEC source: 0001127602-20-013951 · form4.xml · nonDerivative · entry 1

CARMICHAEL GREG D · CIK 0001247734 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 755

F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On April 15, 2020, Encompass Health paid a dividend on its common stock of $0.28 per share and the closing price was $69.76. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.

SEC source: 0001127602-20-010598 · form4.xml · nonDerivative · entry 7

Anthony April Kaye Bullock · CIK 0001629441 · CEO & President, Home Health

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 191,740

F6 · price: This per share price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $60.39 to $61.00, inclusive. The reporting person undertakes to provide to Encompass Health Corporation, any of its security holders, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within this range.

SEC source: 0001127602-20-010598 · form4.xml · nonDerivative · entry 6

Anthony April Kaye Bullock · CIK 0001629441 · CEO & President, Home Health

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 183,657

F5 · price: This per share price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $59.36 to $60.34, inclusive. The reporting person undertakes to provide to Encompass Health Corporation, any of its security holders, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within this range.

SEC source: 0001127602-20-010598 · form4.xml · nonDerivative · entry 5

Anthony April Kaye Bullock · CIK 0001629441 · CEO & President, Home Health

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 163,077

F4 · price: This per share price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $58.35 to $59.35, inclusive. The reporting person undertakes to provide to Encompass Health Corporation, any of its security holders, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within this range.

SEC source: 0001127602-20-010598 · form4.xml · nonDerivative · entry 4

Anthony April Kaye Bullock · CIK 0001629441 · CEO & President, Home Health

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 121,470

F3 · price: This per share price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $57.74 to $58.33, inclusive. The reporting person undertakes to provide to Encompass Health Corporation, any of its security holders, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within this range.

SEC source: 0001127602-20-010598 · form4.xml · nonDerivative · entry 3

Anthony April Kaye Bullock · CIK 0001629441 · CEO & President, Home Health

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 82,588

F2 · price: This per share price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $56.73 to $57.72, inclusive. The reporting person undertakes to provide to Encompass Health Corporation, any of its security holders, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within this range.

SEC source: 0001127602-20-010598 · form4.xml · nonDerivative · entry 2

Anthony April Kaye Bullock · CIK 0001629441 · CEO & President, Home Health

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 71,850

F1 · price: This per share price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $55.72 to $56.72, inclusive. The reporting person undertakes to provide to Encompass Health Corporation, any of its security holders, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within this range.

SEC source: 0001127602-20-010598 · form4.xml · nonDerivative · entry 1

Anthony April Kaye Bullock · CIK 0001629441 · CEO & President, Home Health

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 67,440

SEC source: 0001127602-20-010806 · form4.xml · nonDerivative · entry 1

CORRELL DONALD L · CIK 0001199794 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 70,568

SEC source: 0001127602-20-010358 · form4.xml · nonDerivative · entry 1

Anthony April Kaye Bullock · CIK 0001629441 · CEO & President, Home Health

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 66,740

F1 · price: This per share price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $64.12 to $64.48, inclusive. The reporting person undertakes to provide to Encompass Health Corporation, any of its security holders, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within this range.

SEC source: 0001127602-20-010596 · form4.xml · nonDerivative · entry 1

HIGDON LEO I JR · CIK 0001064587 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 73,738

SEC source: 0001127602-20-009979 · form4.xml · nonDerivative · entry 1

Jacobsmeyer Barbara Ann · CIK 0001691132 · President, Inpatient Hospitals

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 47,261

F1 · kind: Represents shares of Common Stock that the reporting person donated as a gift to a donor advised fund administered by the American Endowment Foundation.

SEC source: 0001127602-20-024412 · form4.xml · nonDerivative · entry 1

Anthony April Kaye Bullock · CIK 0001629441 · CEO & President, Home Health

10b5-1 filing: Not disclosed

Ownership: Indirect · By HCHB Consulting, Inc.

Disclosed balance after: 548,842

F1 · kind: This transaction, described further below, was previously disclosed by Encompass Health Corporation ("EHC") on its Form 8-K, Item 8.01, filed with the Securities and Exchange Commission ("SEC") on February 21, 2020; its Quarterly Report on Form 10-Q, Part II, Item 2, for the quarter ended March 31, 2020; and its Definitive Proxy Statement filed with the SEC on March 27, 2020. On February 20, 2020, EHC entered into an exchange agreement with Ms. Anthony, pursuant to which she had the right to exchange all of her remaining shares of the common stock of Encompass Health Home Health Holdings, Inc. ("Home Health Holdings"), a subsidiary of EHC, valued at approximately $45 million, for shares of common stock of EHC by delivering an exchange notice. Her exchange agreement provided that the number of EHC shares to be delivered equaled the fair value of the shares of Home Health Holdings stock on the date of the exchange agreement, divided by the last reported sales price of EHC common stock on the date of delivery of an exchange notice. On February 20, 2020, EHC also received the exchange notice from Ms. Anthony, on which date the closing price of EHC's common stock was $82.56 per share. Pursuant to the terms of the exchange agreement, on March 6, 2020, EHC delivered 548,842 shares of EHC common stock to Ms. Anthony in exchange for all of her Home Health Holdings stock.

F1 · price: This transaction, described further below, was previously disclosed by Encompass Health Corporation ("EHC") on its Form 8-K, Item 8.01, filed with the Securities and Exchange Commission ("SEC") on February 21, 2020; its Quarterly Report on Form 10-Q, Part II, Item 2, for the quarter ended March 31, 2020; and its Definitive Proxy Statement filed with the SEC on March 27, 2020. On February 20, 2020, EHC entered into an exchange agreement with Ms. Anthony, pursuant to which she had the right to exchange all of her remaining shares of the common stock of Encompass Health Home Health Holdings, Inc. ("Home Health Holdings"), a subsidiary of EHC, valued at approximately $45 million, for shares of common stock of EHC by delivering an exchange notice. Her exchange agreement provided that the number of EHC shares to be delivered equaled the fair value of the shares of Home Health Holdings stock on the date of the exchange agreement, divided by the last reported sales price of EHC common stock on the date of delivery of an exchange notice. On February 20, 2020, EHC also received the exchange notice from Ms. Anthony, on which date the closing price of EHC's common stock was $82.56 per share. Pursuant to the terms of the exchange agreement, on March 6, 2020, EHC delivered 548,842 shares of EHC common stock to Ms. Anthony in exchange for all of her Home Health Holdings stock.

SEC source: 0001127602-20-009350 · form4.xml · derivative · entry 1

Darby John Patrick · CIK 0001664699 · EVP, Gen Counsel & Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,718

Underlying: Encompass Health Common Stock · 9,718 shares

Expires 2030-03-02

F1 · derivative.exercise_date: The option becomes exercisable in annual installments over a three-year period, at the rate of 33.3% per year commencing March 2, 2021.

SEC source: 0001127602-20-009353 · form4.xml · derivative · entry 1

Tarr Mark J · CIK 0001304057 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 55,360

Underlying: Encompass Health Common Stock · 55,360 shares

Expires 2030-03-02

F1 · derivative.exercise_date: The option becomes exercisable in annual installments over a three-year period, at the rate of 33.3% per year commencing March 2, 2021.

SEC source: 0001127602-20-009351 · form4.xml · derivative · entry 1

Jacobsmeyer Barbara Ann · CIK 0001691132 · President, Inpatient Hospitals

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,227

Underlying: Encompass Health Common Stock · 17,227 shares

Expires 2030-03-02

F1 · derivative.exercise_date: The option becomes exercisable in annual installments over a three-year period, at the rate of 33.3% per year commencing March 2, 2021.

SEC source: 0001127602-20-009349 · form4.xml · derivative · entry 1

COLTHARP DOUGLAS E · CIK 0001186879 · EVP & Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,613

Underlying: Encompass Health Common Stock · 20,613 shares

Expires 2030-03-02

F1 · derivative.exercise_date: The option becomes exercisable in annual installments over a three-year period, at the rate of 33.3% per year commencing March 2, 2021.

SEC source: 0001127602-20-009348 · form4.xml · derivative · entry 1

Anthony April Kaye Bullock · CIK 0001629441 · CEO & President, Home Health

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,718

Underlying: Encompass Health Common Stock · 9,718 shares

Expires 2030-03-02

F1 · derivative.exercise_date: The option becomes exercisable in annual installments over a three-year period, at the rate of 33.3% per year commencing March 2, 2021.

SEC source: 0001127602-20-007501 · form4.xml · nonDerivative · entry 2

Tarr Mark J · CIK 0001304057 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 383,065

F1 · shares: These shares were withheld or surrendered to pay the insider's tax withholding obligations incurred in connection with the vesting of the related restricted stock.

SEC source: 0001127602-20-007500 · form4.xml · nonDerivative · entry 2

Price Andrew L · CIK 0001475399 · Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 71,216

F1 · shares: These shares were withheld or surrendered to pay the insider's tax withholding obligations incurred in connection with the vesting of the related restricted stock.

SEC source: 0001127602-20-007499 · form4.xml · nonDerivative · entry 2

Jacobsmeyer Barbara Ann · CIK 0001691132 · President, Inpatient Hospitals

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 48,692

F1 · shares: These shares were withheld or surrendered to pay the insider's tax withholding obligations incurred in connection with the vesting of the related restricted stock.

SEC source: 0001127602-20-007498 · form4.xml · nonDerivative · entry 2

Fay Edmund · CIK 0001433234 · Sr. Vice Pres. and Treasurer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 89,005

F1 · shares: These shares were withheld or surrendered to pay the insider's tax withholding obligations incurred in connection with the vesting of the related restricted stock.